CMMB Q3 2021 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$9,042

Operating Income

-$3M

Net Income

-$3M

EPS (Diluted)

$-1.05

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$67M

Total Liabilities

$2M

Stockholders' Equity

$66M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$9,042	$0	—
Operating Income	-$3M	-$1M	-136.0%
Net Income	-$3M	-$1M	-142.5%